<DOC>
	<DOC>NCT00418587</DOC>
	<brief_summary>The purpose of this study is to test the safety and effectiveness of different doses of vitamin D in patients with Systemic Lupus Erythematosus (SLE). A long term goal is to determine if vitamin D could be used as a treatment and/or preventative of SLE.</brief_summary>
	<brief_title>Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>SLE by ACR criteria (revised 1997) African American, participating in the SLE in Gullah Health (SLEIGH) Study Outpatient Stable disease with no BILAG A or B in any system for the past 4 weeks Stable prednisone (or equivalent corticosteroid) dose ≤ 20 mg/day for ≥ 4 weeks prior to study entry Baseline 25(OH)D concentration of &lt; 30 ng/ml Willingness to discontinue other vitamin D supplements and/or multivitamins containing vitamin D while participating in the study Age 18 85 years Ability to complete questionnaires in English Ability to give informed consent Presence of hypercalcemia (&gt;10.4 mg/dL), hypercalcuria (urinary calcium/creatinine ratio ≥ 0.8 mmol/mmol) or known primary hyperparathyroidism Liver disease (serum ALT, AST &gt;2x normal) or total serum bilirubin &gt;1.5x normal History of renal stones Current treatment with any dose of cyclophosphamide Dialysis or creatinine &gt; 2.5 mg/dL Pregnancy Current drug or alcohol abuse Anticipated poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Lupus</keyword>
</DOC>